BNTX:NSD-BioNTech SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 160.35

Change

0.00 (0.00)%

Market Cap

USD 38.59B

Volume

0.48M

Avg Analyst Target

USD 239.78 (+49.54%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BNTX Stock Forecast & Price:
Based on the BioNTech SE stock forecasts from 10 analysts, the average analyst target price for BioNTech SE is USD 239.78 over the next 12 months. BioNTech SE’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioNTech SE is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, BioNTech SE’s stock price was USD 160.35. BioNTech SE’s stock price has changed by -12.43% over the past week, +3.81% over the past month and -57.50% over the last year.

About BioNTech SE (BNTX:NSD)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/I ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD75.53B 24.40 16.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD68.27B 12.89 9.72
MRNA Moderna Inc

N/A

USD66.97B 5.32 3.83
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

N/A

USD31.38B 55.02 -46.75
RPRX Royalty Pharma Plc

N/A

USD29.88B 43.33 20.93
ALNY Alnylam Pharmaceuticals Inc

N/A

USD28.07B N/A -36.52
GMAB Genmab AS

N/A

USD24.11B 75.33 6.42
ARGX argenx NV ADR

N/A

USD20.75B N/A -20.02
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BNTX

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD0.47B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD0.01B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.10B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

N/A

USD1.36B
FPXI First Trust International.. 0.00 % 0.70 %

N/A

USD0.38B
FPXE First Trust IPOX Europe E.. 0.00 % 0.70 %

N/A

USD6.32M
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

USD0.22B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.10 %

N/A

USD0.04B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.46B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.43B
GERM ETFMG Treatments Testing .. 0.00 % 0.68 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.60 %

N/A

N/A
FBTU:LSE First Trust Global Funds .. 0.00 % 0.60 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.80% 45% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.80% 45% F 29% F
Trailing 12 Months  
Capital Gain -57.50% 44% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.50% 44% F 25% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 120.98% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.98% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 155.98% 13% F 7% F
Risk Adjusted Return 77.56% 98% A+ 95% A
Market Capitalization 38.59B 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.11 60% D- 88% B+
Price/Book Ratio 2.28 49% F 41% F
Price / Cash Flow Ratio 43.37 2% F 7% F
EV/EBITDA 1.77 9% F 47% F
Management Effectiveness  
Return on Equity 105.30% 99% A+ 99% A+
Return on Invested Capital 152.53% 98% A+ 98% A+
Return on Assets 65.18% 100% A+ 100% A+
Debt to Equity Ratio 1.44% 83% B 86% B
Technical Ratios  
Dividend Yield 1.33% 43% F 23% F
Short Ratio 1.59 75% C 71% C-
Short Percent 2.94% 59% F 49% F
Beta -0.08 96% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.